Research

Energy balance

Most societies endorse GLP-1RA therapy in patients with established or high risk of CVD independently of glycaemia.

Clinicians should follow current guidelines endorsing GLP-1RA therapy for patients at high risk for CVD, regardless of their glycaemic control.

StrongSupportsmedium confidence
Subsequently, the place for GLP-1RA therapy has changed over recent years, with most societies endorsing GLP-1RA therapy in patients with established or high risk of CVD independently of glycaemia.
Christine R. Andreasen et al. · Diabetes Obesity and Metabolism · 2021

Why this rating

Based on consensus from multiple societies.

Source

Understanding the place for <scp>GLP‐1RA</scp> therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection

Christine R. Andreasen et al. · Diabetes Obesity and Metabolism · 2021

DOI 10.1111/dom.14500

reviewCited 36×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →